Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Renovaro Biosciences Inc (RENB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Renovaro Biosciences's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.470 -0.110    -6.96%
01/05 - Closed. Currency in USD ( Disclaimer )
Pre Market
1.460
-0.010
-0.680%
4:08:05 - Real-time Data
  • Volume: 450,999
  • Bid/Ask: 1.450 / 1.600
  • Day's Range: 1.450 - 1.610
Type:  Equity
Market:  United States
Renovaro Biosciences 1.470 -0.110 -6.96%

Renovaro Biosciences Inc Company Profile

 
Get an in-depth profile of Renovaro Biosciences Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

12

Equity Type

ORD

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

Contact Information

Address 2080 Century Park East Suite 906
Los Angeles, 90067
United States
Phone 305 918 1980
Fax -

Top Executives

Name Age Since Title
W. David Hardy - 2018 Chairman of HIV Scientific Advisory Board
James R. Sapirstein 62 2018 Independent Director
Mark R. Dybul 60 2018 CEO, Director & Member of HBV Scientific Advisory Board
Gregg Huber Alton 57 2019 Lead Independent Board Member
Jayne McNicol 56 2021 Independent Director
Carol L. Brosgart 71 2019 Chairperson of HBV Cure Scientific Advisory Board & Independent Director
Rene Sindlev 61 2017 Chairman of the Board
Steven G. Deeks - 2018 Member of HIV Scientific Advisory Board
Fabien Zoulim - 2020 Member of HBV Scientific Advisory Board
Anna Suk-fong Lok - 2021 Member of HBV Scientific Advisory Board
Richard James Whitley 78 2021 Member of Respiratory Diseases Scientific Advisory Board
Peter Revill - 2020 Member of HBV Scientific Advisory Board
Rudolphus Gabriel Cornelis Hendriks 77 2023 Independent Director
Avram C. Miller 79 2023 Director
Karen Brink - 2024 Director
Leni Maria Teuntje Boerner 61 2023 Independent Director
Geert Kazemier - 2024 Chairman of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

RENB Comments

Write your thoughts about Renovaro Biosciences Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email